Equities research analysts expect that Five Prime Therapeutics Inc (NASDAQ:FPRX) will post ($1.29) earnings per share for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for Five Prime Therapeutics’ earnings, with estimates ranging from ($1.51) to ($1.04). Five Prime Therapeutics posted earnings per share of ($0.73) in the same quarter last year, which would suggest a negative year-over-year growth rate of 76.7%. The company is scheduled to announce its next quarterly earnings report after the market closes on Tuesday, February 27th.
On average, analysts expect that Five Prime Therapeutics will report full year earnings of ($5.56) per share for the current fiscal year, with EPS estimates ranging from ($5.84) to ($5.38). For the next year, analysts expect that the firm will post earnings of ($5.00) per share, with EPS estimates ranging from ($6.65) to ($3.23). Zacks’ earnings per share averages are an average based on a survey of research firms that follow Five Prime Therapeutics.
Several equities analysts recently weighed in on the company. Royal Bank of Canada boosted their price objective on Five Prime Therapeutics from $41.00 to $50.00 and gave the stock an “outperform” rating in a research report on Monday, November 6th. BMO Capital Markets upped their price target on Five Prime Therapeutics from $71.00 to $75.00 and gave the company an “outperform” rating in a report on Tuesday, November 7th. Zacks Investment Research cut Five Prime Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, November 9th. ValuEngine cut Five Prime Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, November 7th. Finally, BidaskClub cut Five Prime Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, December 9th. Three investment analysts have rated the stock with a sell rating and six have issued a buy rating to the company. Five Prime Therapeutics has a consensus rating of “Hold” and a consensus price target of $64.00.
A number of institutional investors have recently bought and sold shares of the business. MetLife Investment Advisors LLC acquired a new position in Five Prime Therapeutics in the 4th quarter valued at approximately $294,000. Vident Investment Advisory LLC raised its holdings in Five Prime Therapeutics by 46.6% in the 4th quarter. Vident Investment Advisory LLC now owns 59,767 shares of the biotechnology company’s stock valued at $1,310,000 after acquiring an additional 18,994 shares in the last quarter. Platinum Investment Management Ltd. raised its holdings in Five Prime Therapeutics by 201.9% in the 4th quarter. Platinum Investment Management Ltd. now owns 62,800 shares of the biotechnology company’s stock valued at $1,376,000 after acquiring an additional 42,000 shares in the last quarter. Teachers Advisors LLC grew its stake in shares of Five Prime Therapeutics by 4.9% in the 4th quarter. Teachers Advisors LLC now owns 271,703 shares of the biotechnology company’s stock valued at $5,956,000 after purchasing an additional 12,634 shares during the period. Finally, Bain Capital Public Equity Management LLC bought a new stake in shares of Five Prime Therapeutics in the 4th quarter valued at approximately $839,000. 73.98% of the stock is owned by hedge funds and other institutional investors.
Five Prime Therapeutics (NASDAQ:FPRX) opened at $18.34 on Tuesday. Five Prime Therapeutics has a 12-month low of $17.05 and a 12-month high of $49.30. The firm has a market capitalization of $623.76, a PE ratio of -3.62 and a beta of 3.56.
TRADEMARK VIOLATION WARNING: This article was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another website, it was stolen and republished in violation of United States & international copyright law. The legal version of this article can be read at https://www.dispatchtribunal.com/2018/02/20/1-29-earnings-per-share-expected-for-five-prime-therapeutics-inc-fprx-this-quarter.html.
About Five Prime Therapeutics
Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.
Get a free copy of the Zacks research report on Five Prime Therapeutics (FPRX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.